MedReleaf (TSE:LEAF) was downgraded by research analysts at Cormark from a “buy” rating to a “tender” rating in a research note issued to investors on Tuesday.
Several other research firms have also issued reports on LEAF. Beacon Securities restated a “buy” rating and set a C$29.00 price target on shares of MedReleaf in a research report on Tuesday, May 8th. Canaccord Genuity raised their price target on MedReleaf from C$21.50 to C$30.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th.
MedReleaf opened at C$23.94 on Tuesday, according to Marketbeat. MedReleaf has a 1 year low of C$6.81 and a 1 year high of C$31.25.
In related news, insider Ray Leach sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, April 13th. The stock was sold at an average price of C$19.40, for a total transaction of C$1,940,000.00. Also, insider Eitan Popper acquired 27,500 shares of the business’s stock in a transaction dated Tuesday, March 27th. The stock was acquired at an average price of C$18.09 per share, for a total transaction of C$497,475.00. Over the last 90 days, insiders have sold 338,900 shares of company stock worth $6,485,612.
MedReleaf Corp. produces and sells cannabis-based pharmaceutical products in Canada. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. The company was incorporated in 2013 and is headquartered in Markham, Canada.
Receive News & Ratings for MedReleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedReleaf and related companies with MarketBeat.com's FREE daily email newsletter.